{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T15:58:24Z","timestamp":1773503904330,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PiLeJe Laboratoire and supported in part by the R\u00e9gion Pays de la Loire (MibioGate)","award":["ANR-19-CE14-0024"],"award-info":[{"award-number":["ANR-19-CE14-0024"]}]},{"name":"ANR Microbiautism","award":["ANR-19-CE14-0024"],"award-info":[{"award-number":["ANR-19-CE14-0024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Methods: Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Results: Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients\u2019 clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. Conclusions: The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient\u2019s clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS.<\/jats:p>","DOI":"10.3390\/microorganisms11020277","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T03:21:54Z","timestamp":1674616914000},"page":"277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Justine","family":"Marchix","sequence":"first","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-2579","authenticated-orcid":false,"given":"Lucille","family":"Qu\u00e9n\u00e9herv\u00e9","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"},{"name":"Gastroenterology Department, University Hospital of Brest, 29200 Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Bordron","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Aubert","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Durand","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibauld","family":"Oullier","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Blondeau","sequence":"additional","affiliation":[{"name":"PiLeJe Laboratoire, 31-35 rue de la F\u00e9d\u00e9ration, 75015 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-4598","authenticated-orcid":false,"given":"Samira","family":"Ait Abdellah","sequence":"additional","affiliation":[{"name":"PiLeJe Laboratoire, 31-35 rue de la F\u00e9d\u00e9ration, 75015 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Bruley des Varannes","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"},{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, D\u00e9partement de Gastroent\u00e9rologie, CIC 1413, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Chaffron","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, \u00c9cole Centrale Nantes, CNRS, LS2N, UMR 6004, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Coron","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"},{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, D\u00e9partement de Gastroent\u00e9rologie, CIC 1413, IMAD, F-44000 Nantes, France"},{"name":"Gastroenterology and Hepatology Department, University Hospital of Geneva (HUG), 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Neunlist","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, F-44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.3748\/wjg.v18.i30.4012","article-title":"Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome","volume":"18","author":"Ducrotte","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"G799","DOI":"10.1152\/ajpgi.00154.2011","article-title":"Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome","volume":"301","author":"Carroll","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891.x","article-title":"Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12693","DOI":"10.1038\/srep12693","article-title":"Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome","volume":"5","author":"Pozuelo","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.dld.2017.01.142","article-title":"Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis","volume":"49","author":"Liu","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5056\/jnm.2011.17.3.252","article-title":"Irritable bowel syndrome, gut microbiota and probiotics","volume":"17","author":"Lee","year":"2011","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3920\/BM2017.0097","article-title":"New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches","volume":"9","author":"Alard","year":"2018","journal-title":"Benef. Microbes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fcimb.2020.00468","article-title":"Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis","volume":"10","author":"Carco","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/MCG.0b013e318264e918","article-title":"Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome","volume":"46","author":"Barbara","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ishaque, S.M., Khosruzzaman, S.M., Ahmed, D.S., and Sah, M.P. (2018). A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult\u00ae) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol., 18.","DOI":"10.1186\/s12876-018-0788-9"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2169\/internalmedicine.54.2710","article-title":"Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: A meta-analysis","volume":"54","author":"Tiequn","year":"2015","journal-title":"Intern Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3389\/fphar.2020.00332","article-title":"Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/sjg.SJG_384_19","article-title":"Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis","volume":"26","author":"Sun","year":"2020","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"859967","DOI":"10.3389\/fcimb.2022.859967","article-title":"Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.12460","article-title":"Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice\u2014An evidence-based international guide","volume":"38","author":"Hungin","year":"2013","journal-title":"Aliment. Pharmacol. Ther"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1751-0759-6-16","article-title":"The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: A placebo-controlled double-blind crossover trial","volume":"6","author":"Murakami","year":"2012","journal-title":"Biopsychosoc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3164\/jcbn.17-73","article-title":"A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome","volume":"62","author":"Shin","year":"2018","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lewis, E.D., Antony, J.M., Crowley, D.C., Piano, A., Bhardwaj, R., Tompkins, T.A., and Evans, M. (2020). Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients, 12.","DOI":"10.3390\/nu12041159"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Martoni, C.J., Srivastava, S., and Leyer, G.J. (2020). Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients, 12.","DOI":"10.3390\/nu12020363"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"American Gastroenterological Association (2022). Clinical Decision Support Tool: IBS Treatment. Gastroenterology, 163, 152.","DOI":"10.1053\/S0016-5085(22)00536-4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.3748\/wjg.v20.i22.6832","article-title":"Multispecies probiotic protects gut barrier function in experimental models","volume":"20","author":"Harkat","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_24","first-page":"25","article-title":"Premi\u00e8re validation de la version fran\u00e7aise de l\u2019index de qualit\u00e9 de vie pour les maladies digestives (GIQLI)","volume":"23","author":"Slim","year":"1999","journal-title":"Gastroenterol. Clin. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10620-017-4598-7","article-title":"Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity","volume":"62","author":"Pimentel","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sequeira, I.R., Lentle, R.G., Kruger, M.C., Hurst, R.D., and Hogan, S.P. (2014). Standardising the Lactulose Mannitol Test of Gut Permeability to Minimise Error and Promote Comparability. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099256"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2982.2011.01839.x","article-title":"Sacral nerve stimulation enhances epithelial barrier of the rectum: Results from a porcine model","volume":"24","author":"Meurette","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.gie.2018.08.006","article-title":"Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases","volume":"89","author":"David","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.12787","article-title":"Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2014A 12 week double-blind study","volume":"40","author":"Sisson","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Skrzyd\u0142o-Radoma\u0144ska, B., Prozorow-Kr\u00f3l, B., Cicho\u017c-Lach, H., Majsiak, E., Bier\u0142a, J.B., Kanarek, E., Sowi\u0144ska, A., and Cukrowska, B. (2021). The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients, 13.","DOI":"10.3390\/nu13030756"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1756284821993586","DOI":"10.1177\/1756284821993586","article-title":"Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review","volume":"14","author":"Hanning","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pain.2009.06.017","article-title":"Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome","volume":"146","author":"Zhou","year":"2009","journal-title":"Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000333083","article-title":"Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis","volume":"85","author":"Gecse","year":"2012","journal-title":"Digestion"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.3389\/fpain.2021.691689","article-title":"Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients with Irritable Bowel Syndrome","volume":"2","author":"Boonma","year":"2021","journal-title":"Front. Pain Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1365-2036.2008.03818.x","article-title":"Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome","volume":"28","author":"Zeng","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Caviglia, G.P., Tucci, A., Pellicano, R., Fagoonee, S., Rosso, C., Abate, M.L., Olivero, A., Armandi, A., Vanni, E., and Saracco, G.M. (2020). Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082353"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ait Abdellah, S., Gal, C., Laterza, L., Velenza, V., Settanni, C.R., Napoli, M., Schiavoni, E., Mora, V., Petito, V., and Gasbarrini, A. (2022). Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study. Dig. Dis.","DOI":"10.1159\/000526712"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome","volume":"141","author":"Biagi","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e13456","DOI":"10.1111\/nmo.13456","article-title":"The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome","volume":"30","author":"Hod","year":"2018","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12602-010-9059-y","article-title":"Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome","volume":"3","author":"Michail","year":"2011","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5056\/jnm21202","article-title":"Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients with Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial","volume":"28","author":"Shin","year":"2022","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fmicb.2019.00090","article-title":"Lactobacillus plantarum PFM 105 Promotes Intestinal Development Through Modulation of Gut Microbiota in Weaning Piglets","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103293","DOI":"10.1016\/j.ebiom.2021.103293","article-title":"Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?","volume":"66","author":"Deleu","year":"2021","journal-title":"EBioMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/00365521.2019.1624815","article-title":"Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels","volume":"54","author":"Mazzawi","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e14353","DOI":"10.1111\/nmo.14353","article-title":"Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation","volume":"34","author":"Mazzawi","year":"2022","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut Microbiota in Patients with Irritable Bowel Syndrome-A Systematic Review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/CMR.19.1.12-28.2006","article-title":"The Genus Hafnia: From Soup to Nuts","volume":"19","author":"Janda","year":"2006","journal-title":"Clin. Microbiol. Rev."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/2\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:12:00Z","timestamp":1760119920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/2\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["microorganisms11020277"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11020277","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}